Skip Navigation


JAC Advance Access originally published online on January 28, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/3/737    most recent
dkg119v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pattharachayakul, S.
Right arrow Articles by Pendland, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pattharachayakul, S.
Right arrow Articles by Pendland, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 737-739
© 2003 The British Society for Antimicrobial Chemotherapy

Correspondence

Extended-spectrum ß-lactamase (ESBL)-producing Klebsiella pneumoniae: activity of single versus combination agents

S. Pattharachayakul1, M. M. Neuhauser2, J. P. Quinn3 and S. L. Pendland4,*

1 Prince of Songkla University, Department of Clinical Pharmacy, Songkhla, Thailand; 2 University of Houston, Department of Clinical Sciences and Administration, Houston, TX; 3 Rush University, College of Medicine, Chicago, IL; 4 University of Illinois at Chicago, Microbiology Research Laboratory, Department of Pharmacy Practice, 833 South Wood Street, Chicago, IL, USA

Keywords: ESBL, Klebsiella pneumoniae, in vitro, combination activity

The first 10% of the full text of this article appears below.

Sir,

The carbapenems are generally regarded as the drugs of choice for serious infections caused by extended-spectrum ß-lactamase (ESBL)-producing organisms. These agents have demonstrated excellent in vitro activity as well as favourable clinical outcomes. In clinical practice, combination therapy is often utilized despite minimal in vitro and in vivo data. The purpose of this study was to examine the activity of imipenem alone and in combination with amikacin or ciprofloxacin against ESBL-producing strains of K. pneumoniae.

Four clinical isolates of ESBL-producing K. pneumoniae were obtained from the University of Illinois at Chicago Medical Center (Chicago, IL, USA). To determine . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
D. L. Paterson and R. A. Bonomo
Extended-Spectrum {beta}-Lactamases: a Clinical Update
Clin. Microbiol. Rev., October 1, 2005; 18(4): 657 - 686.
[Abstract] [Full Text] [PDF]